How we treat tumor lysis syndrome

Oncology

Volumn 25, Issue 4, 2011, Pages

  Muslimani, Alaa ^a   Chisti, Mohammad Muhsin ^a   Wills, Shannon ^a   Nadeau, Laura ^a   Zakalik, Dana ^a   Daw, Hamed ^b   Huang, James ^a   Jaiyesimi, Ishmael ^a  

^a OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ADENOSINE DEAMINASE INHIBITOR; ALLOPURINOL; ALUMINUM HYDROXIDE; ANTINEOPLASTIC AGENT; BICARBONATE; CORTICOSTEROID; FUROSEMIDE; GLUCONATE CALCIUM; LOOP DIURETIC AGENT; POLYANETHOLESULFONIC ACID; RASBURICASE; URATE OXIDASE;

ACUTE KIDNEY FAILURE; ALKALINIZATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CHRONIC LEUKEMIA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERURICEMIA; HYPERURICOSURIA; HYPOCALCEMIA; LOW DRUG DOSE; NEUROMUSCULAR DISEASE; NONHUMAN; RECOMMENDED DRUG DOSE; REHYDRATION; RENAL REPLACEMENT THERAPY; REVIEW; SEIZURE; SINGLE DRUG DOSE; TETANY; THERAPY DELAY; TREATMENT DURATION; TREATMENT PLANNING; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; URIC ACID NEPHROPATHY;

EID: 79956219002     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med. 1993;94:133-9.
2. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore). 1981;60:218-29.
3. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med. 1980;68:486-91.
4. Bilgrami SF, Fallon BG. Tumor lysis syndrome after combination chemotherapy for ovarian cancer. Med Pediatr Oncol. 1993;21:521-4.
5. Drakos P, Bar-Ziv J, Catane R. Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol. 1994;17:502-5.
6. Fassas AB, Desikan KR, Siegel D, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol. 1999;105:938-41.
7. Gold JE, Malamud SC, LaRosa F, Osband ME. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. Am J Hematol. 1993;44:42-7.
8. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med. 1997;103:363-7.
9. Persons DA, Garst J, Vollmer R, Crawford J. Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. Am J Clin Oncol. 1998;21:426-9.
10. Alkhuja S, Ulrich H. Acute renal failure from spontaneous acute tumor lysis syndrome: a case report and review. Ren Fail. 2002;24:227-32.
11. Jasek AM, Day HJ. Acute spontaneous tumor lysis syndrome. Am J Hematol. 1994;47:129-31.
12. Lotfi M, Brandwein JM. Spontaneous acute tumor lysis syndrome in acute myeloid leukemia? A single case report with discussion of the literature. Leuk Lymphoma. 1998;29:625-8.
13. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Haematologica. 2008;93:1877-85.
14. Malik IA, Abubakar S, Alam F, Khan A. Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma. South Med J. 1994;87:409-11.
15. Tiley C, Grimwade D, Findlay M, et al. Tumour lysis following hydrocortisone prior to a blood product transfusion in T-cell acute lymphoblastic leukaemia. Leuk Lymphoma. 1992;8:143-6.
16. Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol. 2003;72:212-5.
17. Jensen M, Winkler U, Manzke O, et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77:89-91.
18. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1999;62:247-50.
19. Chasty RC, Liu-Yin JA. Acute tumour lysis syndrome. Br J Hosp Med. 1993;49:488-92.
20. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. 2000;27:322-34.
21. Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta. 2003;333:13-8.
22. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-54.
23. Schelling JR, Ghandour FZ, Strickland TJ, Sedor JR. Management of tumor lysis syndrome with standard continuous arteriovenous hemodialysis: case report and a review of the literature. Ren Fail. 1998;20:635-44.
24. Stapleton FB, Strother DR, Roy S, 3rd, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988;82:863-9.
25. Kjellstrand CM, Cambell DC, 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133:349-59.
26. Razis E, Arlin ZA, Ahmed T, et al. Incidence and treatment of tumor lysis syndrome in patients with acute leukemia. Acta Haematol. 1994;91:171-4.
27. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11.
28. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
29. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer. 2003;98:1048-54.
30. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urateoxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol. 2003;21:4402-6.
31. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001; 38:4-8.
32. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia. 2001;15:1505-9.
33. Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma. 2008;8:44-51.
34. Givens ML, Crandall J. Renal complications in oncologic patients. Hematol/Oncol Clin North Am. 2010;24;567-75.
35. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. 1995;9:206-12.
36. Saccente SL, Kohaut EC, Berkow RL. Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration. Pediatr Nephrol. 1995;9:569-73.
37. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol. 2001;19:697-704.
38. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxydase) for the management of hyperuricemia in patients with cancer. Cancer 2003;98:1048-54.
39. Hummel M, Reiter S, Adam K, et al. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol. 2008;80:331-6.
40. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19:34-8.
41. McDonnell AM, Lenz KL, Frei-Lahr DA, et al. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006;26:806-12.
42. Perscribing information for rasburicase [Internet]. Available from: http://products.sanofi-aventis.us/elitek/elitek.html.
43. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:27-67.